万维提示：
1、投稿方式：在线投稿。
2、官网网址：https://journal.hep.com.cn/tnn
（主办单位学报编辑部进入）
3、投稿系统：
https://mc.manuscriptcentral.com/tnn
4、主办单位官网：https://xuebao.ccmu.edu.cn/
5、官网电话：010-83911349
6、官网邮箱：
tmr@ccmu.edu.cn
syxuebao@ccmu.edu.cn
liangmy@hep.com.cn
7、出刊日期：季刊，一年出版四期。
8、编辑部信息：《转化神经科学电子杂志（英文）》更名为《转化神经病学与神经外科电子杂志（英文）》（Translational Neurology and Neurosurgery）
2026年4月22日星期三
《转化神经病学与神经外科电子杂志（英文）》稿约
【主办单位微信公众号信息】
首都医科大学学报2026年4月2日 18:00
为进一步拓展神经科学学科领域、强化临床转化特色，经主管部门批准，原《转化神经科学电子杂志（英文）》(Journal of Translational Neuroscience, JTN)自2025年起正式更名为《转化神经病学与神经外科电子杂志（英文）》(Translational Neurology and Neurosurgery, TNN)。
本刊由中国教育部主管，高等教育出版社和首都医科大学共同主办，依托首都医科大学神经科学学科群及附属医院的科研与临床资源，致力于构建一个国际化、开放式的神经病学与神经外科学学术交流平台。主编为吉训明院士，领导编委会和编辑团队严格把关学术质量与出版规范。
改名后，期刊的研究范围更加广泛，涵盖神经系统疾病的基础研究、临床研究、手术创新与技术转化等领域，重点关注神经损伤修复、脑功能重建、神经调控、神经影像学、脑–机接口、人工智能与脑科学融合等前沿方向。
本刊为季刊（每年4期），全英文出版，实行严格的国际同行评审制度，坚持学术诚信、公正透明与开放获取（Open Access）的出版原则，促进神经科学与神经外科的交叉融合与成果转化。感谢广大作者、审稿专家及读者长期以来的信任与支持，欢迎国内外科研人员和临床医生积极投稿，共同推动神经科学与神经外科的学术创新与转化发展。
征稿方向与指南：
鼓励投稿基础与临床结合的高质量论文，包括神经疾病基础机制、手术创新、影像学研究、脑–机接口、神经康复、AI辅助神经科学等前沿领域；
接受原创研究、综述、短篇通讯、病例报告及会议论文成果转化稿件；
优先考虑具有创新性和转化价值的研究，鼓励跨学科、国际合作团队投稿；
所有稿件均需英文撰写，并遵循本刊投稿规范及伦理要求。
稿件提交要求：
请以微软 Word 标准文档（.DOC）格式提交稿件，建议将包括表格和图片在内的所有内容整合为一个文件统一上传。同时，请通过期刊的投稿系统（https://journal.hep.com.cn/tnn）完成提交。
作者在投稿时务必附上投稿信。投稿信中应包含以下关键信息：提交者的完整姓名；论文的完整标题；所有作者的完整姓名及所属机构（所属机构应具体至：部门、大学或机构、城市、邮政编码、州/省、国家）；通讯作者的电子邮箱；通讯作者的通讯地址、电话及传真号码。
《首都医科大学学报》编辑部
《转化神经病学与神经外科电子杂志（英文）》（Translational Neurology and Neurosurgery, TNN）(CN 11-9378/R; ISSN 2097-7492)（https://journal.hep.com.cn/tnn）由中国教育部主管，高等教育出版社和首都医科大学共同主办，致力于构建一个国际化、开放式的神经病学与神经外科学学术交流平台。主编为吉训明院士。
本刊为季刊（每年4期），全英文出版，实行严格的同行评审制度，坚持学术诚信、公正透明与开放获取（Open Access）的出版原则，促进神经科学与神经外科的交叉融合与成果转化。欢迎国内外科研人员和临床医生积极投稿，共同推动神经科学与神经外科的学术创新与转化发展。
期刊网址：
https://journal.hep.com.cn/tnn
在线投稿：
https://mc.manuscriptcentral.com/tnn
咨询信箱：
tmr@ccmu.edu.cn (Zhuang Y)
或syxuebao@ccmu.edu.cn (Zhang JJ)
咨询电话：
010-83911349
Author guidelines
【官网信息】
1. Manuscript Types
This journal accepts the following article types: original research, reviews, short communications, case reports, and others. We encourage high-quality manuscripts that integrate basic and clinical research, particularly in the areas of:
l Neural disease mechanisms
l Surgical innovation
l Neuroimaging
l Brain-machine interfaces
l Neurorehabilitation
l AI-assisted neuroscience
Priority will be given to manuscripts with strong innovative and translational value, especially those involving cross-disciplinary or international collaborations.
2. Manuscript Structure
Articles should be organized into the following sections:
2.1 Title Page
l Full title: The title should be informative, specific to the project, yet concise (75 characters or fewer).
l Authors’ full names: Include all authors and their institutional affiliations in the order of contribution.
l Institutional affiliations: Include department names, institutions, cities, and countries.
l Corresponding author: Name, full address (including postal code), and email address (We strongly recommend that you use an institutional or professional email address, e.g., from your university or organization, rather than a QQ email address).
2.2 Abstract
For original research, reviews, short communications, case reports, and others, provide a structured abstract of ≤ 300 words, containing Objective, Method, Result, and Conclusion.
2.3 Keywords
For original research, reviews, short communications, case reports, and others:
l Provide up to 10 keywords, separated by semicolons.
l We suggest that keywords do not replicate those used in the title. Use specific terms that highlight the essential aspects of the study.
2.4 Main Text
URLs are not allowed to appear in main text.
2.4.1 Introduction
The introduction should put the focus of the manuscript into a broader context and should supply sufficient background information to allow the reader to understand and evaluate the results without referring to previous publications on the topic.
2.4.2 Methods
This section should include sufficient technical information to enable the experiments to be reproduced. Protocols for new methods or significant modifications to existing methods should be included, while previously published or well-established protocols should only be referenced.
2.4.3 Results
This section should provide statistical analyses of all of the experiments that are required to support the conclusions of the paper. Present the results as concisely as possible in text, table(s), or figure(s). Avoid extensive use of graphs to present data that might be more concisely presented in the text or tables. Tables and figures should be numbered consecutively using Arabic numerals and referred to in the text by number, and be sure to cite all figures and tables. Please afford high quality and high-resolution images. Tables should be typed as text, please do not use graphics software to create tables.
2.4.4 Discussion
The discussion should provide an interpretation of the results in relation to previously published work and to the experimental system used. This section should spell out the major conclusions of the work along with some explanation or speculation on the significance of these conclusions. The discussion should be concise and tightly argued.
2.5 Figures and Tables
● Resolution: Figures should be ≥ 300 dpi (JPEG/PNG), ≥ 600 dpi (line art).
● Titles and Legends: Figures and tables must have descriptive titles and legends. The first word and proper nouns should be capitalized.
● Editable files for figures and tables must be provided.
● URLs are not allowed to appear in figures or tables.
l Numbering and captions for composite figures:
—Primary figures (main figures): Use Figure 1, Figure 2, etc.
—Subfigures within a composite figure: Use (a), (b), (c), etc.
—Sub-subfigures (smaller units within a subfigure): Use (i), (ii), (iii), etc.
—The names and descriptions of subfigures should be included within the main figure caption.
—Descriptions of the smallest units (i), (ii), ... should be placed in the figure legend (note) directly below the main caption. Use a smaller or different font, separate individual descriptions with semicolons, and end the entire note with a period.
2.6 Acknowledgments
(if no, please write “Not applicable”)
2.7 Authors’ contributions
(Required)
2.8 Fundings
(if no, please write “Not applicable”)
2.9 Ethics approval and consent to participate
(Required)
Example: The Research Ethics Commission of Beijing Tongren Hospital, Capital Medical University (TRECKY2020–013) approved the study. All participants provided written informed consent for an interview, as well as follow-up interviews and blood sample collection.
And for clinical trials, if the clinical research is registered on the clinical research platform, please provide the platform name, and the trial registration number.
If any of the above is not applicable to this study, please explain why.
2.10 Disclosure of artificial intelligence (AI) use
(Required)
If any AI-assisted technologies (e.g., large language models, text generators, coding assistants, image processors) were used in the preparation of this work, the authors must explicitly declare:
l The name and version of the AI tool(s) used.
l The specific purpose(s) of use (e.g., language polishing, data analysis, image enhancement, literature summarization).
l The sections of the manuscript where AI was applied.
And the authors must declare that “The authors are solely and fully responsible for the entire content of this manuscript, including its accuracy, integrity, and ethical compliance. The use of AI tools does not diminish authorial responsibility.”
If no AI used, please state that “All authors declare that no AI was used in the writing and publication of this article.”
2.11 Competing interests
(Required)
Example: The authors declare that they have no competing interests.
2.12 Consent for publication
(Required)
Example: All the authors consent to the publication of identifiable details, which can include figures and data details within the text to be published by Translational Neurology and Neurosurgery.
2.13 Data availability statement
(Required)
Example: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation/The data supporting this study are available in [Repository Name] at [Accession Number]..
（if no, please write “Not applicable”）
2.14 References
No URLs (e.g., www, http, .com, .cn, etc.) are included. Please adhere to the following reference formatting guidelines:
l Provide complete information: Each reference should give readers enough details to locate the original article.
l Pay attention to formatting details: Please be mindful of spelling, capitalization, and punctuation.
l Number references by order of citation: References should be numbered in the order they first appear in the text; do not alphabetize them.
l Use superscript numbers for citations: In the text, tables, and figure legends, identify references with superscript Arabic numerals, e.g., [1, 6–10].
l Abbreviate journal titles: When listing references, abbreviate journal names according to the Index Medicus.
l List authors correctly: For each reference, list the first three authors; if there are additional authors, add "et al." after the third.
Reference Type
Example
Journal article-print
Salwachter AR, Freischlag JA, Sawyer RG, et al. The training needs and priorities of male and female surgeons and their trainees. J Am Coll Surg. 2005;201:199–205.
Journal article–online (from a database)
Calhoun D, Trimarco T, Meek R, Locasto D. Distinguishing diabetes: Differentiate between type 1 & type 2 DM. JEMS. November 2011; 36(11):32–48. Available from: CINAHL Plus with Full Text, Ipswich, MA. Accessed February 2, 2012.
News–print
Wolf W. State’s mail-order drug plan launched. Minneapolis Star Tribune. May 14, 2004:1B.
News–online
Pollack A. FDA approves new cystic fibrosis drug. New York Times. January 31, 2012. Accessed February 1, 2012.
Web page
Outbreak notice: Cholera in Haiti. Centers for Disease Control and Prevention website. Published October 22, 2010. Updated January 9, 2012. Accessed February 1, 2012.
Book
Modlin J, Jenkins P. Decision Analysis in Planning for a Polio Outbreak in the United States. San Francisco, CA: Pediatric Academic Societies; 2004.
Book chapter
Solensky R. Drug allergy: desensitization and treatment of reactions to antibiotics and aspirin. In: Lockey P, ed. Allergens and Allergen Immunotherapy. 3rd ed. New York, NY: Marcel Dekker; 2004:585–606.
Authors are responsible for the accuracy and completeness of their references and for correct citation of the text.
3. Manuscript Submission
Please submit your files in MS Word - standard DOCUMENT (.DOC) formats, and recommend you upload your entire manuscript, including tables and figures, as a single file. And please submit your files through the journal’s submission system (https://mc.manuscriptcentral.com/tnn).
It is important that authors include a cover letter with their manuscript. The letter should contain all important details such as: your full name (submitted by); full title of article; full list of authors with affiliations (Affiliations should include: Department; University or organization; City; Postal code; State/province; Country); e-mail of the corresponding author; contact address, telephone/fax numbers of the corresponding author.
4. Preprint Policy
● Manuscripts posted on non-peer-reviewed preprint servers (e.g., bioRxiv, medRxiv, arXiv, HEP Preprint) are accepted.
● Authors must disclose preprint details (DOI/URL) during submission.
Pubdate: Apr 13, 2026
